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Abstract
Background: Polycystic ovarian syndrome (PCOS) is a common reproductive endocrine disease that is seen among
adolescent women. Currently, there is limited evidence to support treatment options leading to considerable variation
in practice among healthcare specialists. The objective of this study is to review and synthesize all the available evidence
on treatment options for PCOS among adolescent women.
Methods/design: We will conduct a systematic review of all randomized controlled trials evaluating the use of
metformin, oral contraceptive pills as monotherapy, or as combination with pioglitazone, spironolactone, flutamide,
and lifestyle interventions in the treatment of PCOS in adolescent women ages 11 to 19 years. The primary outcome
measures are menstrual regulation and change hirsutism scores. The secondary outcome measures include acne
scores, prevalence of dysglycaemia, BMI, lipid profile, total testosterone level, and adverse events. We will perform
literature searches through Ovid Medline, Ovid Embase, and Cochrane Central Register of Controlled Trials (CENTRAL),
and gray literature resources. Two reviewers will independently screen titles and abstracts of identified citations, review
the full texts of potentially eligible trials, extract information from eligible trials, and assess the risk of bias and quality of
the evidence independently. Results of this review will be summarized narratively and quantitatively as appropriate. We
will perform a multiple treatment comparison using network meta-analysis to estimate the pooled direct and indirect
effects for all PCOS interventions on outcomes if adequate data is available.
Discussion: PCOS treatment poses a clinical challenge to the patients and physicians. This is the first systematic review
and network meta-analysis for PCOS treatment in adolescents. We expect that our results will help improve patient care,
unify the treatment approaches among specialists, and encourage research for other therapeutic options.
Systematic review registration: PROSPERO CRD42015016148
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Dysglycaemia
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Background
Polycystic ovarian syndrome (PCOS) is a common repro-
ductive endocrine disease encountered among adolescents
and young women [1]. Its prevalence varies between 1.8
and 15 % depending on the diagnostic criteria used and
ethnicity [1–3]. Patients with PCOS can present with a
constellation of symptoms including chronic anovulation
(amenorrhea, oligomenorrhea, irregular menstrual cycles),
clinical features of hyperandrogenism (acne and hirsut-
ism), biochemical evidence of hyperandrogenism, polycys-
tic ovaries on ultrasound, and features of metabolic
syndrome. Oligomenorrhea is the presenting feature in
about 75 % of cases [4], while hirsutism and acne are
present in 60–70 % of cases and contribute to psycho-
logical distress in adolescent patients [4, 5].
Three different diagnostic criteria have been used for
the diagnosis of PCOS: the National Institutes of Health
(NIH), the Rotterdam, and the Androgen Excess Society
Criteria [6–8]. All of them require the presence of men-
strual cycle disturbance and presence of clinical and/or
biochemical hyperandrogenism, while the last two re-
quire the presence of polycystic ovarian morphology on
ultrasound [6, 7]. To date, the preferred diagnostic cri-
teria in adolescents are the NIH criteria [9, 10].
The etiology of PCOS is complex and not well under-
stood. Primary intrinsic ovarian pathology in combination
with hypothalamic–pituitary–ovarian axis abnormalities
may lead to increased ovarian androgen secretion [11, 12].
Insulin resistance with compensatory hyperinsulinemia
may also play a role as it can lead to direct stimulation of
ovarian and adrenal androgen secretion, which leads to
decreased hepatic sex hormone binding globulin synthesis
and therefore, to an increased bioavailability of free testos-
terone level [11–14]. Insulin resistance is involved in the
development of cardiometabolic disturbances such as dys-
glycaemia, hyperlipidemia, and obesity [15–17], and it has
been described that between 18 and 24 % of adolescents
with PCOS have some degree of abnormal glucose me-
tabolism [18–20]. These patients are at increased risk
of type 2 diabetes, hypertension, myocardial infarction,
angina, and psychiatric diseases [21, 22] in addition to
gynecological and obstetrical complications, such as in-
fertility, higher rate for pregnancy loss, gestational dia-
betes, premature delivery, as well as gynecological and
non-gynecological cancers [22–26]. In addition to the
aforementioned co-morbidities, patients with PCOS ex-
perience a low perceived health quality over lack of
symptom improvement, primarily with weight control,
hirsutism, acne, menstrual irregularity, and infertility as
inferred from qualitative studies [27–29].
Optimal first line treatment of PCOS in adolescents
remains controversial. Current Endocrine Society treatment
guidelines first recommend lifestyle changes (dietary and
exercise modification) followed by either oral contraceptive
pills (OCP) to control symptoms of hyperandrogenism
or metformin therapy in patients with impaired glucose
tolerance or features of metabolic syndrome [10]. How-
ever, there is significant variability in clinical practice,
depending on whether the physician and patient’s primary
goal of treatment is to treat the symptoms of hyperandro-
genism or the features of metabolic syndrome [30, 31].
Additionally, in clinical practice anti-androgenic medica-
tions such as spironolactone, flutamide, and insulin sensi-
tizing agents such as pioglitazone are used as add-on
therapy when OCP or metformin fail to produce the
clinically desired outcomes [4, 31], yet the Endocrine
Society guidelines do not comment on their use in
the adolescent population.
To date, there is one systematic review and meta-
analyses in adolescents (in press) that identified low num-
ber of low quality evidence from head-to head trials and
identified large number of trials that compared metformin
to placebo, OCP to placebo, and other PCOS combination
therapy [32]. A traditional meta-analysis can only evaluate
the direct treatment efficacy of two treatment approaches
at a time while a network meta-analysis can provide effect
estimates for all direct and indirect treatment comparisons
[33]. Therefore, we aim to conduct a network meta-
analysis to address the following objectives: (1) assess the
effectiveness and safety of using metformin and OCP as
monotherapy in adolescents with PCOS; (2) assess the ef-
fectiveness and safety of using metformin and/or OCP in
combination with pioglitazone, spironolactone, flutamide,
and lifestyle interventions, as evaluated across multiple
outcomes such as menstrual cycle regulation, improve-
ment in clinical and or biochemical evidence of hyperan-
drogenism, and metabolic profile in adolescents with
PCOS; (3) evaluate the effectiveness of different formula-
tions of OCPs on hirsutism and acne scores.
Methods/design
This systematic review and network meta-analysis proto-
col is registered on PROSPERO International prospective
register of systematic reviews (CRD42015016148). The re-
port will comply with the Preferred Reporting Items for
Systematic Review and Network Meta-Analysis Protocols
(PRISMA-P) [34].
Eligibility criteria
The search for studies will be limited to randomized
clinical trials (RCT) (including all designs such as cross-
over, cluster, and patient-randomized clinical trials) asses-
sing the efficacy, effectiveness, or safety of different
regimen for the treatment of PCOS that enrolled adoles-
cent girls ages 11–19 years. The definition of adolescent
age group is based on the widely accepted World Health
Organization definition for adolescent [35]. Studies that
include both adolescents and adults participants will be
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included in the review, and upon contact, we will ask au-
thors to provide separate data for the adolescent partici-
pants. If we are unable to obtain this information, we will
include the study and we will conduct subgroup analyses
in order to assess the difference between studies which in-
cluded only adolescents and studies which included both
adolescents and adults. Sub-studies or secondary ana-
lysis of reported eligible studies will be excluded to
avoid duplication.
The diagnosis of PCOS will be based on the known
PCOS diagnostic criteria: Endocrine Society Guidelines,
NIH criteria, Rotterdam criteria, and the Androgen Excess
Society criteria [6, 7, 10]. We will exclude studies that in-
cluded normal control participants or patients with other
causes of oligomenorrhea or hyperandrogenism, such as
hyperprolactinemia, thyroid dysfunction, androgen secret-
ing tumors, or late-onset congenital adrenal hyperplasia.
We will include studies that evaluated single and/or
combined interventions, at any dose, such as metformin,
OCP, pioglitazone, spironolactone, flutamide, and life-
style interventions. In order to be included, the study
will have had to report the effectiveness of one of these
interventions and the intervention effect on one or more
of the outcomes of interest.
Our primary outcomes are menstrual cycle regulation
and hirsutism scores. The secondary outcomes include
acne scores, prevalence of dysglycaemia, BMI, total tes-
tosterone level, lipid profile (triglyceride, total choles-
terol, LDL, HDL), and adverse events; Table 1 shows the
definitions of outcome measures. We chose not to re-
port on pregnancy outcomes because it necessities chan-
ging the scope of the review to involve fertility induction
medications. Hence, we will exclude studies that only
used fertility induction medications and which primary
outcome of interest was pregnancy.
Data sources and search strategy
We performed literature search through Ovid MEDLINE,
Ovid EMBASE, and Cochrane Central Register of Con-
trolled Trials (CENTRAL) from the database inception to
January 2015 using combination of controlled terms, i.e.,
Medical Subject Heading (MeSH), Emtree terms, and
free-text terms with various synonyms for polycystic
ovarian syndrome (PCOS), adolescent, metformin, pio-
glitazone, oral contraceptive pills, flutamide, and life-
style interventions (Appendix).
We used the randomized controlled trial filter created
from McMaster University for Ovid Embase platform
and the Cochrane library filter for Ovid Medline platform
[36, 37]. These filters provide a good balance between sensi-
tivity and specificity. Our search strategy was developed in
liaison with an experienced librarian. No language, publica-
tion status, or date limit was used. Additionally, we per-
formed a gray literature search through (1) manual hand
search of bibliographies of identified randomized controlled
trials and guidelines; (2) trials registries (Clinicaltrials.gov,
World Health Organization WHO International Clinical
Trials Registry Platform Search Portal, controlled-trials.com
and the National Institutes of Health database of funded
studies for ongoing or unpublished trials); and (3) confer-
ences preceding and abstracts of the North American and
European Endocrine Society and The Society of Adolescent
Medicine and Health. Search alerts are set up for monthly
notification, and the search will be repeated before the final
manuscript submission to identify any new literature. We
will contact the authors of unpublished work to establish
eligibility and methodological quality of the study.
Study selection
Two reviewers (RA and IF) will independently and in
duplicate screen the title and abstract available of identi-
fiable articles to assess its eligibility. In case of disagree-
ment, the full text will be retrieved and reviewed
independently by one of the authors (EB), to resolve dis-
crepancy. We will refer to inclusion and exclusion cri-
teria during the screening process. Records of ineligible
articles along with the reason for ineligibility will be
saved for future reference. Eligible articles citations will
be saved in EndnoteX6 library. We will include the
PRISMA flow diagram demonstrating the search and
screening process (Fig. 1). We will contact authors of
primary studies during data extraction to provide any
missing information.
Data extraction
The study data will be collected in standardized online
data extraction forms (Google forms) according to pre-
specified instructions. The data extraction form will
include information pertaining to study background, lan-
guage of publication, country, funding sources, confirm
study eligibility, participant ages, PCOS diagnostic cri-
teria, the study design, number of intervention groups,
intervention details, number of participants allocated to
each intervention group, randomization, concealment of
allocation, blinding, length of follow up, analysis type,
outcome definition, unit of measurement, ascertainment
of the outcome, estimate of intervention effect with con-
fidence interval, and missing follow up data. When stud-
ies measure outcomes at more than one time point, we
will collect results for the last measurement point in the
study. The data extraction form will be pilot tested by all
reviewers independently before its use. Four reviewers
will perform data extraction (RA, IF, EB, BD), working
in pairs independently and in duplicate. In case of dis-
agreement in assessing the methodological quality of the
study, we will try to resolve it by consensus. If consensus
cannot be reached, a third designated reviewer from the
team will be involved.
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Table 1 Outcome measures
Outcome Measurement of variable (units) Statistical estimates and
measurement of association
of this outcome
Menstrual regulation Number of girls achieved regular menses Rate ratio
Number of cycles per year Mean difference ± SD
Hirsutism Ferriman Gallawey score Mean difference ± SD
Acne scores Lesion counting or grading Standardized mean difference ± SD
Dysglycaemia The rate of occurrence of T2DM, impaired glucose tolerance,
and impaired fasting glucose assessed by oral glucose tolerance
test and/or fasting blood glucose, and/or HBA1c
Rate ratio
BMI kg/m2 Mean difference ± SD
Total testosterone level ng/ml Mean difference ± SD
Total cholesterol mg/dl Mean difference ± SD
LDL mg/dl Mean difference ± SD
HDL mg/dl Mean difference ± SD
Triglyceride mg/dl Mean difference ± SD
Adverse events Number of girls developed: OR, rate ratio
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Assessment of risk of bias in included studies
Two independent reviewers will assess each included study
for risk of bias using the modified Cochrane handbook for
systematic reviews of interventions tool [37], which as-
sesses six elements: (1) sequence generation, (2) allocation
concealment, (3) blinding of participants, personnel and
outcome assessors, (4) completeness of follow up, (5) se-
lective outcome reporting, and 6) presence of other biases.
Each domain will be assigned a score of “low risk,” “high
risk,” or “unclear risk.” We will further categorize the “un-
clear risk” to “probably low risk” or “probably high risk” in
order to give a better understanding of the unclear risk of
bias score. We will rate the overall risk of bias score for
each study as “high risk” if the study meets more than two
criteria for high risk of bias, “moderate risk of bias” if the
study meets one to two criteria for high risk of bias, and
“low risk of bias” if the study does not meet any high risk
of bias criteria [38].
Standard direct comparisons
We will perform a pairwise meta-analysis using R soft-
ware. Effect estimates and their 95th confidence interval
(CI) will be calculated using risk ratio (RR) for binary
outcomes and mean difference for continuous outcomes
if they are reported using the same metrics; otherwise,
estimates reported using different metrics will be con-
verted into standardized mean difference (SMD). We
will pool all direct evidence using random-effect meta-
analysis with the maximal likelihood (ML) estimator
[39]. We will assess for heterogeneity by estimating the
variance between studies using the chi-square test and
quantify it using the I2 test statistic. We will interpret
the I2 using the thresholds set forth by the Cochrane
Collaboration [37].
The network meta-analysis
Given that many of the treatment combinations available
to treat PCOS were not compared in head-to-head stud-
ies, a network meta-analysis (NMA) will be necessary to
provide effect estimates for all indirect comparisons
[33]. We will perform a multiple treatment comparison
to estimate the pooled direct, indirect, and the network
Table 1 Outcome measures (Continued)















OR odds ratio, T2DM type 2 diabetes mellitus, BMI body mass index, LDL low-density lipoprotein, HDL high-density lipoprotein, GI gastrointestinal
Fig. 1 The primary selection process
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estimates (mixed evidence from direct and indirect esti-
mates) for all PCOS interventions on outcomes if the as-
sumptions of homogeneity and similarity are judged to
be reasonable. Effect estimates will be presented along
with their corresponding 95 % credibility intervals (CrIs);
these are the Bayesian analog of 95 % CIs. However,
mixed evidence will only be used if the consistency as-
sumption is met.
We will fit a Bayesian random-effect hierarchical
model with non-informative priors using vague normal
distribution (mean 0, variance 10,000) and adjusting for
correlation between effects in multi-arm trials. We will
generate posterior samples using Markov Chain
Monte-Carlo (MCMC) simulation technique running
the analysis in four parallel chains. We will use a series
of 100,000 burn-in simulations to allow convergence
and then a further 20,000 simulations (succeeding
50,000 simulations saved at an interval of 10 in each
chain) to produce the outputs. We will assess model
convergence using Gelman and Rubin diagnostic test [40].
The Bayesian model provides flexibility for moderate
levels of treatment heterogeneity, sampling variability,
and incoherence [41]. This model introduces a ran-
dom effect representing any changes in the observed
treatment effect that may be due to the comparison
being made [42]. We will interpret variability in this
random effect as incoherence [41]. We will use the
node-splitting method to detect incoherence between
direct and indirect evidence within a closed loop as
well as identify loops with large inconsistency [42, 43].
We will measure the goodness-of-fit of the model using
the deviance information criterion (DIC) [42].
To ensure interpretability of the NMA results, we will
present the network geometry, the results with probabil-
istic statements, and also the estimates of interventions
effects and corresponding 95 % CrIs, as well as forest
plots. We will first rank the intervention and report each
interventions’ probability of ranking first (being the best
treatment) as well as the surface under the cumulative
ranking curve (SUCRA) values [44]. High SUCRA values
are expected for the best treatments, and low SUCRA
values are expected for the worst treatments.
The above analysis assumes that the interventions are
competing (suitable when most components forming an
intervention are pharmaceutical and hence cannot go to-
gether), so that each combination is considered to be a
separate treatment. For example, a combination of com-
ponents of metformin, flutamide, and exercise forming an
intervention and another combination of metformin and
exercise forming another intervention are treated as com-
peting interventions and assesses whether one combination
is better than another. However, it is possible to perform
the network meta-analysis treating these combinations as
complex intervention [45]. Such an analysis fits a similar
hierarchical regression model but considers multiple com-
ponents of an intervention as dummy variables in the same
model. Hence, the analysis allows the estimation of the ef-
fects and ranking of a combination of all possible and ap-
propriate components. Thus, it is possible to explore such
a combination that could have been the best for the treat-
ment of PCOS but has never been tested before in any
trial. Further, such an analysis allows the assessment of
additive or multiplicative (interaction) effects between two
or more components if sufficient data are available. We
will re-analyze the data under complex intervention ap-
proach as well [45] to assess if there exists a potentially bet-
ter combination of components which have been ever or
never assessed.
We will perform the Bayesian network meta-analysis
in JAGS (version 3.4.0) or WinBUGS software (version
1.4.3, MRC Biostatistics Unit, Cambridge, UK) inter-
facing through R software.
Meta-regression
In case there is significant heterogeneity and inconsistency,
we will use meta-regression to explain the heterogeneity,
provided we have enough data to do so; otherwise, we will
perform subgroup analyses. We will perform meta-
regression using study level covariates: methodological
quality (high risk of bias versus low risk of bias), partici-
pant’s average age, BMI status (obese and/or overweight
BMI ≥25 kg/m2 versus normal <25 kg/m2), homeostatic
model assessment (HOMA-IR) (high and moderate ≥3
versus low <3), medication dose, length of treatment
(≥3 months versus <3 months), use of ultrasound to docu-
ment polycystic ovaries (used versus not used), and studies
that included young adults versus adolescents only to
examine the improvement or change in model fit after co-
variates are included into the model. We will also perform
a subgroup analysis to evaluate the effectiveness of differ-
ent oral formulations of contraceptive pill on changes of
hirsutism and acne scores.
Rating the confidence in estimates of the effect in NMA
The confidence in the estimates (quality of evidence) for
each reported outcome will be assessed independently
by two reviewers (RA, IF) using the Grading of Recom-
mendations Assessment, Development, and Evaluation
Working Group (GRADE Working Group) approach;
see Fig. 2 for the flow of quality assessment [46]. The
quality of evidence is categorized by GRADE into four
levels: high quality, moderate quality, low quality, and
very low quality. For the direct comparisons, we will as-
sess and rate each outcome based on the five GRADE
categories: risk of bias, imprecision, inconsistency, indir-
ectness, and publication bias [47].
For the assessment of confidence in the estimates ob-
tained in the NMA, we will use the recent approach
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recommended by the GRADE working group [48]. We
will assess and rate the confidence in all the indirect com-
parisons, if available, obtained from first order loops fol-
lowing the five GRADE categories used for assessing the
direct comparisons in addition to the intransitivity assess-
ment. Then, we will rate the confidence in each NMA ef-
fect estimate using the higher quality rating when both
direct and indirect evidence are present. However, the es-
timate can be rated down for incoherence [48].
Discussion
PCOS treatment in adolescents poses clinical chal-
lenges to patients and physicians. To our best know-
ledge, our study will be the first NMA in adolescents
to investigate the effectiveness and safety of using
metformin and OCP as monotherapy as well as in
combination with pioglitazone, spironolactone, fluta-
mide, or lifestyle interventions.
Our planned approach for this review has many
strengths. We will implement a wide search strategy that
included published and unpublished work. As adolescent
women share some similar physiology with adult women
and in an effort to overcome publication bias, we also
plan to include studies that included adolescents and
young adults. Additionally, we aim to report on many
patient important outcomes as inferred from previous
qualitative research. Similar to previous systematic re-
views in adults with PCOS, we anticipate that we will
identify studies which use different definitions of PCOS,
various definitions for outcome measures of interest,
and small sample sizes [49]. These factors may pose po-
tential limitations to our study.
We hope that this review will provide hierarchical evi-
dence to improve patient care, help unify the treatment
approaches among specialists, and encourage research
for new therapeutic options.
Appendix
Fig. 2 The quality assessment flow diagram
Table 2 Search strategy: Ovid MEDLINE(R) in-process and other
non-indexed citations, Ovid MEDLINE(R) Daily and Ovid
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Table 2 Search strategy: Ovid MEDLINE(R) in-process and other
non-indexed citations, Ovid MEDLINE(R) Daily and Ovid
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